Ironwood Pharmaceuticals' reaffirmation of its FY23 revenue outlook, which aligns with the estimated $441.42M, indicates that the company's financial expectations remain stable. This could potentially maintain investor confidence, but it's unlikely to significantly move the stock price in the short term.